S80082
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/5/15 21:01:16
- 訪問次數(shù) 195
聯(lián)系方式:何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請說明是化工儀器網(wǎng)上看到的信息,謝謝!
- 提示:詳情請下載說明書。
- 產(chǎn)品描述: GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity
- 靶點(diǎn): IC50: 27 nM (IGF-1R), 25 nM (IR)
- 體內(nèi)研究: GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice. GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice. GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice
- 參考文獻(xiàn):
1. Sabbatini P, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res, 2009, 15(9), 3058-3067. 2. Zhou Q, et, al. GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration. Mol Med Rep. 2015 Sep;12(3):3381-3385.
- 溶解度: Soluble in DMSO
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.174 ml 5.869 ml 11.738 ml 5 mM 0.235 ml 1.174 ml 2.348 ml 10 mM 0.117 ml 0.587 ml 1.174 ml 50 mM 0.023 ml 0.117 ml 0.235 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的性,僅供客戶參考交流研究之用。